CY1121251T1 - Σκευασματα που σταθεροποιουν και αναστελλουν την καταβυθιση ανοσογονων συνθεσεων - Google Patents
Σκευασματα που σταθεροποιουν και αναστελλουν την καταβυθιση ανοσογονων συνθεσεωνInfo
- Publication number
- CY1121251T1 CY1121251T1 CY20191100130T CY191100130T CY1121251T1 CY 1121251 T1 CY1121251 T1 CY 1121251T1 CY 20191100130 T CY20191100130 T CY 20191100130T CY 191100130 T CY191100130 T CY 191100130T CY 1121251 T1 CY1121251 T1 CY 1121251T1
- Authority
- CY
- Cyprus
- Prior art keywords
- stabilize
- immunogenic compositions
- compositions
- immunographic
- inhere
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Η παρούσα εφεύρεση ασχολείται με μια υπάρχουσα ανάγκη της τεχνικής για βελτίωση της σταθερότητας ανοσογόνων συνθέσεων όπως συζευγμάτων πολυσακχαρίτη-πρωτεΐνης και πρωτεϊνικών ανοσογόνων. Η εφεύρεση σχετίζεται γενικά με νέα σκευάσματα που σταθεροποιούν κι αναστέλλουν την καταβύθιση ανοσογόνων συνθέσεων. Ειδικότερα, η εφεύρεση που περιγράφεται στη συνέχεια ασχολείται με μια ανάγκη στην τεχνική για σκευάσματα που σταθεροποιούν κι αναστέλλουν το σχηματισμό σωματιδίων (π.χ. συσσωμάτωση, καταβύθιση) ανοσογόνων συνθέσεων που έχουν υποστεί επεξεργασία, ανάπτυξη, παρασκευή σκευάσματος, παρασκευή, και/ή αποθήκευση σε μέσα περιέκτη όπως δοχεία ζύμωσης, βιοαντιδραστήρες, φιαλίδια, φιάλες, σάκους, σύριγγες, ελαστικά πώματα, σωληνώσεις κλπ.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US79526106P | 2006-04-26 | 2006-04-26 | |
EP07760907.1A EP2010219B1 (en) | 2006-04-26 | 2007-04-19 | Formulations which stabilize and inhibit precipitation of immunogenic compositions |
PCT/US2007/066959 WO2007127665A2 (en) | 2006-04-26 | 2007-04-19 | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1121251T1 true CY1121251T1 (el) | 2020-05-29 |
Family
ID=38441477
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20151101066T CY1116966T1 (el) | 2006-04-26 | 2015-11-26 | Νεα σκευασματα που σταθεροποιουν κι αναστελλουν την καταβυθιση ανοσογονων συνθεσεων |
CY20191100130T CY1121251T1 (el) | 2006-04-26 | 2019-01-30 | Σκευασματα που σταθεροποιουν και αναστελλουν την καταβυθιση ανοσογονων συνθεσεων |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20151101066T CY1116966T1 (el) | 2006-04-26 | 2015-11-26 | Νεα σκευασματα που σταθεροποιουν κι αναστελλουν την καταβυθιση ανοσογονων συνθεσεων |
Country Status (30)
Country | Link |
---|---|
US (3) | US7935787B2 (el) |
EP (5) | EP2679244B1 (el) |
JP (7) | JP5612305B2 (el) |
KR (9) | KR20170122857A (el) |
CN (4) | CN104857524B (el) |
AR (2) | AR060665A1 (el) |
AU (1) | AU2007243019B2 (el) |
BR (2) | BRPI0710918B8 (el) |
CA (3) | CA2803111C (el) |
CL (1) | CL2007001185A1 (el) |
CR (1) | CR10405A (el) |
CY (2) | CY1116966T1 (el) |
DK (4) | DK2679245T3 (el) |
EA (2) | EA017436B1 (el) |
ES (4) | ES2910432T3 (el) |
FR (1) | FR22C1027I1 (el) |
HK (3) | HK1196546A1 (el) |
HR (3) | HRP20151203T1 (el) |
HU (5) | HUE055682T2 (el) |
IL (3) | IL194753A (el) |
LT (2) | LT2676679T (el) |
MX (3) | MX359741B (el) |
PL (4) | PL2010219T3 (el) |
PT (4) | PT2679244T (el) |
RU (1) | RU2482878C2 (el) |
SI (4) | SI2679244T1 (el) |
TR (1) | TR201902402T4 (el) |
TW (1) | TW200806315A (el) |
WO (1) | WO2007127665A2 (el) |
ZA (1) | ZA200809167B (el) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2304065T3 (es) | 1998-05-01 | 2008-09-01 | Novartis Vaccines And Diagnostics, Inc. | Antigenos y composiciones de neisseria meningitidis. |
AU783894B2 (en) | 1999-05-19 | 2005-12-22 | Novartis Vaccines And Diagnostics S.R.L. | Combination neisserial compositions |
RU2281956C2 (ru) | 1999-10-29 | 2006-08-20 | Чирон С.Р.Л. | Антигенные пептиды neisseria |
CN100473663C (zh) | 2000-02-28 | 2009-04-01 | 启龙股份公司 | 奈瑟球菌蛋白质的异源表达 |
GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
GB0121591D0 (en) | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
GB0408977D0 (en) | 2004-04-22 | 2004-05-26 | Chiron Srl | Immunising against meningococcal serogroup Y using proteins |
GB0419408D0 (en) * | 2004-09-01 | 2004-10-06 | Chiron Srl | 741 chimeric polypeptides |
US7955605B2 (en) * | 2005-04-08 | 2011-06-07 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
TW200806315A (en) | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
US8808707B1 (en) | 2006-05-08 | 2014-08-19 | Wyeth Llc | Pneumococcal dosing regimen |
US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
JP2011507816A (ja) * | 2007-12-21 | 2011-03-10 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | マラリア用ワクチン |
CA2716212A1 (en) | 2008-02-21 | 2009-08-27 | Novartis Ag | Meningococcal fhbp polypeptides |
CA2756522C (en) | 2009-03-24 | 2018-06-26 | Novartis Ag | Adjuvanting meningococcal factor h binding protein |
JP5668049B2 (ja) * | 2009-03-24 | 2015-02-12 | ノバルティス アーゲー | 髄膜炎菌h因子結合タンパク質および肺炎球菌糖結合体の組み合わせ |
RU2536248C2 (ru) | 2009-04-30 | 2014-12-20 | Коули Фармасьютикал Груп, Инк. | Пневмококковая вакцина и ее применения |
KR101609032B1 (ko) * | 2010-06-04 | 2016-04-04 | 와이어쓰 엘엘씨 | 스트렙토코커스 뉴모니아 백신 제제 |
US8802603B2 (en) | 2010-06-17 | 2014-08-12 | Becton, Dickinson And Company | Medical components having coated surfaces exhibiting low friction and low reactivity |
US10478483B2 (en) | 2010-06-25 | 2019-11-19 | Glaxosmithkline Biologicals Sa | Combinations of meningococcal factor H binding proteins |
RU2580620C2 (ru) | 2010-08-23 | 2016-04-10 | ВАЙЕТ ЭлЭлСи | СТАБИЛЬНЫЕ КОМПОЗИЦИИ АНТИГЕНОВ Neisseria meningitidis rLP2086 |
PE20140173A1 (es) | 2010-09-10 | 2014-02-20 | Wyeth Llc | Variantes no lipidadas de antigenos orf2086 de neisseria meningitidis |
FR2966044B1 (fr) * | 2010-10-18 | 2012-11-02 | Sanofi Pasteur | Procede de conditionnement d'un vaccin contenant un adjuvant d'aluminium |
TWI603739B (zh) | 2010-11-11 | 2017-11-01 | 艾伯維生物技術有限責任公司 | 具有增進高濃度之抗-TNFα抗體之液體調配物 |
AR084158A1 (es) * | 2010-12-10 | 2013-04-24 | Merck Sharp & Dohme | Formulaciones que mitigan la agregacion inducida por agitacion de composiciones inmunogenicas |
WO2013098589A1 (en) | 2011-12-29 | 2013-07-04 | Novartis Ag | Adjuvanted combinations of meningococcal factor h binding proteins |
SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
MY198910A (en) | 2012-03-09 | 2023-10-02 | Pfizer | Neisseria meningitidis compositions and methods thereof |
JP2015521595A (ja) | 2012-06-14 | 2015-07-30 | ノバルティス アーゲー | 血清群x髄膜炎菌のためのワクチン |
ES2912082T3 (es) | 2012-06-26 | 2022-05-24 | Lg Electronics Inc | Método de decodificación de vídeo, método de codificación de vídeo y medio de almacenamiento legible por decodificador que almacena información de video codificada |
JOP20200175A1 (ar) * | 2012-07-03 | 2017-06-16 | Novartis Ag | حقنة |
EP2964665B1 (en) | 2013-03-08 | 2018-08-01 | Pfizer Inc | Immunogenic fusion polypeptides |
MX369534B (es) | 2013-09-08 | 2019-11-11 | Pfizer | Composiciones de neisseria meningitidis y sus metodos. |
PL3060256T3 (pl) * | 2013-10-25 | 2019-10-31 | Bayer Pharma AG | Nowa stabilna formulacja |
US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
AU2015208821B2 (en) * | 2014-01-21 | 2017-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
CN107249626A (zh) | 2015-02-19 | 2017-10-13 | 辉瑞大药厂 | 脑膜炎奈瑟球菌组合物及其方法 |
BR112017026343A2 (pt) * | 2015-06-08 | 2019-11-19 | Serum Inst Of India Private Ltd | métodos para aperfeiçoar a adsorção de conjugados de proteína-polissacarídeo e formulação de vacina multivalente assim obtida |
KR102225282B1 (ko) * | 2015-07-21 | 2021-03-10 | 화이자 인코포레이티드 | 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도 |
US10702606B2 (en) * | 2015-12-10 | 2020-07-07 | Menicon Co., Ltd. | Peptide composition |
MX2019002489A (es) | 2016-09-02 | 2019-10-21 | Sanofi Pasteur Inc | Vacuna contra neisseria meningitidis. |
MA47223A (fr) | 2016-12-30 | 2019-11-06 | Sutrovax Inc | Conjugués polypeptide-antigène avec des acides aminés non naturels |
US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
CN106620681A (zh) * | 2017-01-12 | 2017-05-10 | 南京佰泰克生物技术有限公司 | 一种细胞裂解液、试剂盒及在制备肿瘤全细胞抗原负载dc肿瘤疫苗中的应用 |
SG11201906519RA (en) | 2017-01-31 | 2019-08-27 | Pfizer | Neisseria meningitidis compositions and methods thereof |
CN110225764A (zh) | 2017-01-31 | 2019-09-10 | 默沙东公司 | 制备多糖-蛋白缀合物的方法 |
EP3576759A4 (en) | 2017-01-31 | 2020-11-11 | Merck Sharp & Dohme Corp. | PROCESS FOR THE PREPARATION OF CAPSULE POLYSACCHARIDE PROTEIN CONJUGATES FROM STREPTOCOCCUS PNEUMONIAE SEROTYPE 19F |
US20200061542A1 (en) * | 2017-02-24 | 2020-02-27 | Merck Sharp & Dohme Corp. | Methods for improving filterability of polysaccharide-protein conjugate reactions |
WO2018156468A1 (en) * | 2017-02-24 | 2018-08-30 | Merck Sharp & Dohme Corp. | Pneumococcal conjugate vaccine formulations |
CA3050120A1 (en) | 2017-02-24 | 2018-08-30 | Merck Sharp & Dohme Corp. | Enhancing immunogenicity of streptococcus pneumoniae polysaccharide-protein conjugates |
KR20200051005A (ko) | 2017-09-07 | 2020-05-12 | 머크 샤프 앤드 돔 코포레이션 | 폐렴구균 폴리사카라이드 및 면역원성 폴리사카라이드-담체 단백질 접합체에서의 그의 용도 |
MX2020002557A (es) | 2017-09-07 | 2020-07-13 | Merck Sharp & Dohme | Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina. |
CN111278458A (zh) * | 2017-10-25 | 2020-06-12 | 默沙东公司 | 佐剂疫苗 |
SG11202005255PA (en) | 2017-12-06 | 2020-07-29 | Merck Sharp & Dohme | Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
EP3788143B1 (en) | 2018-04-30 | 2023-06-28 | Merck Sharp & Dohme LLC | Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide |
KR20210005158A (ko) | 2018-04-30 | 2021-01-13 | 머크 샤프 앤드 돔 코포레이션 | 스트렙토코쿠스 뉴모니아에 피막 폴리사카라이드 담체 단백질 접합체를 제조하는 방법 |
US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
CN113272423A (zh) * | 2018-09-24 | 2021-08-17 | 拜奥维萨有限责任公司 | 双半抗原化自体疫苗及其用途 |
TWI788610B (zh) | 2018-12-19 | 2023-01-01 | 美商默沙東有限責任公司 | 包含肺炎鏈球菌多醣-蛋白質結合物之組合物及其使用方法 |
KR20230150339A (ko) | 2021-02-26 | 2023-10-30 | 바이오로지칼 이 리미티드 | 활성화 켄칭된 다당류, 및 백신 조성물 중의 다당류의 정량화를 위한 개선된 방법 |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1189340A (en) * | 1967-09-13 | 1970-04-22 | American Cyanamid Co | Antigen-Adjuvant Composition |
US4673574A (en) | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
US4902506A (en) | 1983-07-05 | 1990-02-20 | The University Of Rochester | Immunogenic conjugates |
SE8405493D0 (sv) | 1984-11-01 | 1984-11-01 | Bror Morein | Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel |
US5078996A (en) | 1985-08-16 | 1992-01-07 | Immunex Corporation | Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
FR2630115B1 (fr) * | 1988-04-14 | 1994-10-28 | Merieux Inst | Procede de stabilisation des solutions d'albumine humaine et solution obtenue |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
DE69114390T2 (de) * | 1990-07-19 | 1996-06-05 | Nardino Righi | Sicherheitsspritze zum einmaligen Gebrauch. |
CA2059692C (en) * | 1991-01-28 | 2004-11-16 | Peter J. Kniskern | Pneumoccoccal polysaccharide conjugate vaccine |
IL101715A (en) | 1991-05-02 | 2005-06-19 | Amgen Inc | Recombinant dna-derived cholera toxin subunit analogs |
JPH07507854A (ja) | 1991-12-23 | 1995-08-31 | ツォッヒェ,ミヒャエル | 油除去装置を備えたエンジン |
IT1253009B (it) | 1991-12-31 | 1995-07-10 | Sclavo Ricerca S R L | Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini |
DK0671948T3 (da) | 1992-06-25 | 1997-09-01 | Smithkline Beecham Biolog | Vaccinepræparat indeholdende adjuvanser |
EP0616034B1 (en) | 1993-03-05 | 2004-10-20 | Wyeth Holdings Corporation | Plasmid for production of CRM protein and diphtheria toxin |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
JP3696267B2 (ja) | 1994-02-28 | 2005-09-14 | 天野エンザイム株式会社 | 生理活性蛋白質の安定化方法 |
DE4407489A1 (de) * | 1994-03-07 | 1995-09-14 | Bayer Ag | Vakzine zur Prävention von Respirations- und Reproduktionserkrankungen des Schweines |
US5571515A (en) | 1994-04-18 | 1996-11-05 | The Wistar Institute Of Anatomy & Biology | Compositions and methods for use of IL-12 as an adjuvant |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
US6355255B1 (en) | 1998-12-07 | 2002-03-12 | Regents Of The University Of Minnesota | Streptococcal C5a peptidase vaccine |
US5846547A (en) | 1996-01-22 | 1998-12-08 | Regents Of The University Of Minnesota | Streptococcal C5a peptidase vaccine |
US6403098B1 (en) | 1996-09-26 | 2002-06-11 | Merck & Co., Inc. | Rotavirus vaccine formulations |
RU2098109C1 (ru) * | 1996-09-26 | 1997-12-10 | Александр Григорьевич Чучалин | Противоаллергическое, противовоспалительное средство, способ его получения, лечебное и косметическое средства с его использованием |
US5932223A (en) | 1996-09-26 | 1999-08-03 | Merck & Co., Inc. | Rotavirus vaccine formulations |
JP4078406B2 (ja) * | 1997-01-22 | 2008-04-23 | 有限会社コーキ・エンジニアリング | 注射器のシリンダの製造方法 |
AU739829B2 (en) * | 1997-04-08 | 2001-10-18 | Merck Sharp & Dohme Corp. | Stabilized human papillomavirus formulations |
US6113918A (en) * | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
FR2763244B1 (fr) * | 1997-05-14 | 2003-08-01 | Pasteur Merieux Serums Vacc | Composition vaccinale multivalente a porteur mixte |
US6224880B1 (en) * | 1997-09-24 | 2001-05-01 | Merck & Co., Inc. | Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines |
CA2264970A1 (en) * | 1998-03-10 | 1999-09-10 | American Cyanamid Company | Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria |
JP4673974B2 (ja) | 1998-09-30 | 2011-04-20 | ワイス・ホールディングズ・コーポレイション | アジュバントとしての変異コレラホロトキシン |
EP1880735A3 (en) | 1999-03-19 | 2008-03-12 | GlaxoSmithKline Biologicals S.A. | Vaccine |
GB9909077D0 (en) | 1999-04-20 | 1999-06-16 | Smithkline Beecham Biolog | Novel compositions |
GB9928196D0 (en) * | 1999-11-29 | 2000-01-26 | Chiron Spa | Combinations of B, C and other antigens |
PT1233784E (pt) * | 1999-12-02 | 2008-11-03 | Novartis Vaccines & Diagnostic | Composições e métodos para a estabilização de moléculas biológicas após a liofilização |
DE10012370A1 (de) * | 2000-03-14 | 2001-09-27 | Chiron Behring Gmbh & Co | Adjuvans für Vakzinen |
WO2001093905A1 (en) | 2000-06-08 | 2001-12-13 | Intercell Biomedizinische Forschungs- Und Entwicklungs Ag | Immunostimulatory oligodeoxynucleotides |
GB0108364D0 (en) * | 2001-04-03 | 2001-05-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
CA2783274C (en) * | 2000-06-29 | 2018-08-07 | Glaxosmithkline Biologicals S.A. | Multivalent vaccine composition with reduced dose of haemophilus influenza type b |
KR100385711B1 (ko) * | 2000-07-05 | 2003-05-27 | 녹십자백신 주식회사 | 디프테리아, 파상풍 톡소이드와 백일해균 및b형간염표면항원을 포함한 4가 혼합백신 및 그 제조방법 |
AU7193501A (en) * | 2000-07-10 | 2002-01-21 | Us Health | Multiple antigenic peptides immunogenic against streptococcus pneumoniae |
GB0025414D0 (en) * | 2000-10-16 | 2000-11-29 | Consejo Superior Investigacion | Nanoparticles |
AT410635B (de) | 2000-10-18 | 2003-06-25 | Cistem Biotechnologies Gmbh | Vakzin-zusammensetzung |
WO2002074325A1 (en) * | 2001-03-19 | 2002-09-26 | Iomai Corporation | Patch for transcutaneous immunization |
WO2002098369A2 (en) | 2001-06-07 | 2002-12-12 | Wyeth Holdings Corporation | Mutant forms of cholera holotoxin as an adjuvant |
JP2004535187A (ja) | 2001-06-07 | 2004-11-25 | ワイス・ホールデイングス・コーポレーシヨン | アジュバントとしてのコレラホロトキシンの突然変異形 |
GB0115176D0 (en) * | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
EP1409013B1 (en) * | 2001-07-26 | 2009-11-18 | Novartis Vaccines and Diagnostics S.r.l. | Vaccines comprising aluminium adjuvants and histidine |
MX339524B (es) * | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
KR100913714B1 (ko) * | 2001-11-08 | 2009-08-24 | 패시트 바이오테크 코포레이션 | Igg 항체의 안정한 액상 약학 제형물 |
WO2004065603A2 (en) | 2003-01-15 | 2004-08-05 | Wyeth Holdings Corporation | Methods for increasing neisseria protein expression |
WO2004067030A2 (en) * | 2003-01-30 | 2004-08-12 | Chiron Srl | Injectable vaccines against multiple meningococcal serogroups |
JP4728948B2 (ja) * | 2003-02-10 | 2011-07-20 | エラン ファーマシューティカルズ,インコーポレイテッド | 免疫グロブリン製剤およびその調製の方法 |
US20060251675A1 (en) | 2003-03-17 | 2006-11-09 | Michael Hagen | Mutant cholera holotoxin as an adjuvant and an antigen carrier protein |
US20070253964A1 (en) * | 2003-04-16 | 2007-11-01 | Zlotnick Gary W | Novel Immunogenic Compositions for the Prevention and Treatment of Meningococcal Disease |
NZ544367A (en) * | 2003-06-25 | 2009-12-24 | Elan Pharm Inc | Combination therapy involving methotrexate for treating rheumatoid arthritis |
UA67144A (en) | 2003-07-29 | 2004-06-15 | Inst Exprm & Clinical Veterina | Method for production of inactivated vaccine against salmonellosis and escherichiosis of animals |
EP2366403B1 (en) | 2003-08-06 | 2014-10-08 | The Government of The United States of America, as represented by The Secretary, Department of Health and Human Services | Polysaccharide-protein conjugate vaccines |
DE10348550A1 (de) * | 2003-10-20 | 2005-06-16 | Hexal Biotech Forschungsgmbh | Stabile wässrige G-CSF-haltige Zusammensetzungen |
RU37462U1 (ru) | 2004-01-16 | 2004-04-27 | Бычкова Ольга Владимировна | Пробирка |
WO2006050341A2 (en) * | 2004-11-01 | 2006-05-11 | The Brigham And Women's Hospital, Inc. | Modified streptococcal polysaccharides and uses thereof |
TW200638943A (en) * | 2005-01-28 | 2006-11-16 | Wyeth Corp | Stabilized liquid polypeptide formulations |
US7709001B2 (en) | 2005-04-08 | 2010-05-04 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
US7955605B2 (en) | 2005-04-08 | 2011-06-07 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
US20070184072A1 (en) | 2005-04-08 | 2007-08-09 | Wyeth | Multivalent pneumococcal polysaccharide-protein conjugate composition |
ME01334B (me) * | 2005-04-08 | 2013-12-20 | Wyeth Llc | Polivalentni pripravak konjugata pneumokoknog polisaharida s proteinom |
GB0524066D0 (en) * | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
US20070253985A1 (en) | 2006-04-26 | 2007-11-01 | Wyeth | Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations |
TW200806315A (en) | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
WO2009109550A1 (en) | 2008-03-05 | 2009-09-11 | Sanofi Pasteur | Process for stabilizing an adjuvant containing vaccine composition |
-
2007
- 2007-04-12 TW TW096112884A patent/TW200806315A/zh unknown
- 2007-04-19 PT PT131864530T patent/PT2679244T/pt unknown
- 2007-04-19 PL PL07760907T patent/PL2010219T3/pl unknown
- 2007-04-19 HU HUE13186454A patent/HUE055682T2/hu unknown
- 2007-04-19 SI SI200732187T patent/SI2679244T1/sl unknown
- 2007-04-19 PL PL13186454T patent/PL2679245T3/pl unknown
- 2007-04-19 US US11/737,674 patent/US7935787B2/en active Active
- 2007-04-19 KR KR1020177031015A patent/KR20170122857A/ko active Application Filing
- 2007-04-19 RU RU2008141680/15A patent/RU2482878C2/ru active
- 2007-04-19 HU HUE07760907A patent/HUE028137T2/hu unknown
- 2007-04-19 CA CA2803111A patent/CA2803111C/en active Active
- 2007-04-19 EP EP13186453.0A patent/EP2679244B1/en active Active
- 2007-04-19 CN CN201510239424.8A patent/CN104857524B/zh active Active
- 2007-04-19 EP EP19155604.2A patent/EP3517129A1/en active Pending
- 2007-04-19 BR BRPI0710918A patent/BRPI0710918B8/pt active IP Right Grant
- 2007-04-19 KR KR1020087028865A patent/KR101514847B1/ko active IP Right Review Request
- 2007-04-19 ES ES13186453T patent/ES2910432T3/es active Active
- 2007-04-19 MX MX2014003400A patent/MX359741B/es unknown
- 2007-04-19 KR KR1020207007952A patent/KR20200032268A/ko not_active Application Discontinuation
- 2007-04-19 HU HUE13186453A patent/HUE058394T2/hu unknown
- 2007-04-19 KR KR20147030833A patent/KR20140132779A/ko active Application Filing
- 2007-04-19 DK DK13186454.8T patent/DK2679245T3/da active
- 2007-04-19 SI SI200732180T patent/SI2679245T1/sl unknown
- 2007-04-19 ES ES13185292T patent/ES2712956T3/es active Active
- 2007-04-19 EA EA200870480A patent/EA017436B1/ru active Protection Beyond IP Right Term
- 2007-04-19 EP EP13186454.8A patent/EP2679245B1/en active Active
- 2007-04-19 CN CN201610269964.5A patent/CN105879021B/zh active Active
- 2007-04-19 BR BR122020000285-9A patent/BR122020000285B1/pt active IP Right Grant
- 2007-04-19 JP JP2009507900A patent/JP5612305B2/ja active Active
- 2007-04-19 KR KR1020137033305A patent/KR101514913B1/ko active IP Right Review Request
- 2007-04-19 CN CN2007800147343A patent/CN101500612B/zh active Active
- 2007-04-19 KR KR1020187034525A patent/KR102093269B1/ko active IP Right Grant
- 2007-04-19 EP EP07760907.1A patent/EP2010219B1/en active Active
- 2007-04-19 WO PCT/US2007/066959 patent/WO2007127665A2/en active Application Filing
- 2007-04-19 CN CN201310587301.4A patent/CN103768615B/zh active Active
- 2007-04-19 KR KR1020217027284A patent/KR20210111326A/ko not_active Application Discontinuation
- 2007-04-19 KR KR1020227013826A patent/KR20220061256A/ko not_active Application Discontinuation
- 2007-04-19 SI SI200732093T patent/SI2676679T1/sl unknown
- 2007-04-19 EP EP13185292.3A patent/EP2676679B1/en active Active
- 2007-04-19 LT LTEP13185292.3T patent/LT2676679T/lt unknown
- 2007-04-19 TR TR2019/02402T patent/TR201902402T4/tr unknown
- 2007-04-19 DK DK07760907.1T patent/DK2010219T3/en active
- 2007-04-19 ES ES07760907.1T patent/ES2557504T3/es active Active
- 2007-04-19 AU AU2007243019A patent/AU2007243019B2/en active Active
- 2007-04-19 PT PT13185292T patent/PT2676679T/pt unknown
- 2007-04-19 CA CA2873346A patent/CA2873346C/en active Active
- 2007-04-19 PL PL13185292T patent/PL2676679T3/pl unknown
- 2007-04-19 DK DK13185292.3T patent/DK2676679T3/en active
- 2007-04-19 MX MX2008013572A patent/MX2008013572A/es active IP Right Grant
- 2007-04-19 DK DK13186453.0T patent/DK2679244T3/da active
- 2007-04-19 PT PT131864548T patent/PT2679245T/pt unknown
- 2007-04-19 CA CA2650056A patent/CA2650056C/en active Active
- 2007-04-19 PL PL13186453T patent/PL2679244T3/pl unknown
- 2007-04-19 EA EA201200929A patent/EA023470B1/ru active Protection Beyond IP Right Term
- 2007-04-19 PT PT77609071T patent/PT2010219E/pt unknown
- 2007-04-19 KR KR1020167011184A patent/KR20160049063A/ko active Application Filing
- 2007-04-19 ES ES13186454T patent/ES2885762T3/es active Active
- 2007-04-19 HU HUE13185292A patent/HUE042923T2/hu unknown
- 2007-04-19 SI SI200731706T patent/SI2010219T1/sl unknown
- 2007-04-25 CL CL2007001185A patent/CL2007001185A1/es unknown
- 2007-04-26 AR ARP070101814A patent/AR060665A1/es not_active Application Discontinuation
-
2008
- 2008-10-22 IL IL194753A patent/IL194753A/en active IP Right Grant
- 2008-10-22 MX MX2018012171A patent/MX2018012171A/es unknown
- 2008-10-24 ZA ZA200809167A patent/ZA200809167B/xx unknown
- 2008-10-28 CR CR10405A patent/CR10405A/es unknown
-
2011
- 2011-03-24 US US13/070,664 patent/US20110172393A1/en not_active Abandoned
-
2012
- 2012-09-28 US US13/631,573 patent/US8562999B2/en active Active
-
2013
- 2013-11-19 JP JP2013239284A patent/JP2014055169A/ja not_active Withdrawn
-
2014
- 2014-07-14 JP JP2014144436A patent/JP6192115B2/ja active Active
- 2014-10-08 HK HK14110032.3A patent/HK1196546A1/zh unknown
-
2015
- 2015-07-05 IL IL239788A patent/IL239788A0/en active IP Right Grant
- 2015-07-16 IL IL239978A patent/IL239978B/en active IP Right Grant
- 2015-10-16 HK HK15110177.7A patent/HK1209358A1/xx unknown
- 2015-11-10 HR HRP20151203TT patent/HRP20151203T1/hr unknown
- 2015-11-26 CY CY20151101066T patent/CY1116966T1/el unknown
-
2016
- 2016-07-27 JP JP2016147591A patent/JP6321094B2/ja active Active
- 2016-10-18 HK HK16111995.4A patent/HK1223569A1/zh unknown
-
2018
- 2018-01-05 AR ARP180100033A patent/AR110731A2/es not_active Application Discontinuation
- 2018-04-03 JP JP2018071339A patent/JP2018123145A/ja not_active Withdrawn
-
2019
- 2019-01-29 HR HRP20190198TT patent/HRP20190198T1/hr unknown
- 2019-01-30 CY CY20191100130T patent/CY1121251T1/el unknown
- 2019-07-10 JP JP2019128073A patent/JP2019194240A/ja active Pending
-
2021
- 2021-08-03 JP JP2021127528A patent/JP2021176910A/ja active Pending
- 2021-09-07 HR HRP20211417TT patent/HRP20211417T1/hr unknown
-
2022
- 2022-06-08 LT LTPA2022509C patent/LTPA2022509I1/lt unknown
- 2022-06-09 FR FR22C1027C patent/FR22C1027I1/fr active Active
- 2022-06-09 HU HUS2200028C patent/HUS2200028I1/hu unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1121251T1 (el) | Σκευασματα που σταθεροποιουν και αναστελλουν την καταβυθιση ανοσογονων συνθεσεων | |
CY1118243T1 (el) | Νεα κατασκευασματα μεταφορεα και μορια συζευγματος φορτιου μεταφορεα | |
Nguyen et al. | Site‐specific N‐terminal labeling of peptides and proteins using butelase 1 and thiodepsipeptide | |
CY1121233T1 (el) | Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα καtα του υποδοχεα iντερλευκinης-4(ιl-4r) | |
CY1119436T1 (el) | Σκευασμα για αντισωμα εναντι- 4 7 | |
AR119287A2 (es) | Composición que comprende una molécula de factor viii unida a un polímero hidrosoluble | |
CY1120854T1 (el) | Συνθεσεις λιποπεπτιδιου και σχετικες μεθοδοι | |
CY1125300T1 (el) | Φαρμακευτικες συνθεσεις που περιεχουν οξειδιο-υδροξειδιο του σιδηρου | |
NO20062687L (no) | Immunogene peptidbaererkonjugater og fremgangsmater for fremstilling av samme | |
AR127861A2 (es) | Composición farmacéutica que comprende inhibidores del proteasoma peptídico y ciclodextrina | |
CY1119256T1 (el) | Βελτιωμενες συνθεσεις και μεθοδοι για λυοφιλοποιηση και προϊοντα λυοφιλοποιησης που παρεχονται απο αυτες | |
EA200870264A1 (ru) | Композиция антител | |
AR088460A1 (es) | Formulaciones de etanercept estabilizadas con aminoacidos | |
CY1120585T1 (el) | Εναιωρηματα νανοσωματιδιων που περιεχουν πολυμερες καρβοξυβινυλιου | |
DE602006019629D1 (de) | Von zellen stammende virale impfstoffe mit geringen mengen an rest-zell-dna | |
CY1119038T1 (el) | Φαρμακευτικο εναιωρημα | |
CY1111489T1 (el) | Ενωσεις για την αναστολη του πρωτεασωματος | |
MX362981B (es) | Moleculas artificiales de acido nucleico para la expresion mejorada de proteina o peptido. | |
EP2598661A4 (en) | COMPOSITIONS FOR STABILIZING DNA, RNA AND PROTEINS IN STORAGE AND OTHER BIODEGRADES DURING TRANSPORT AND STORAGE IN AMBIENT TEMPERATURES | |
CY1113173T1 (el) | Λιποπεπτιδικες ελικοειδεις δεσμες διπλης ελικωσης και συνθετικα ιο-μορφα σωματιδια | |
CY1113069T1 (el) | Μεθοδοι παρασκευης συνθεσεων ξηρης σκονης του γλυκοπυρρολικου | |
CY1121964T1 (el) | Αντισωματα εναντιον toy csf-1r | |
NO20080830L (no) | Transportmidler for a krysse blod-hjernebarrierer og inn i hjerne-kreftceller, og fremgangsmate for bruk derav | |
EA200870615A1 (ru) | Производные лептомицина | |
CY1106824T1 (el) | Σταθερες ενεσιμες συνθεσεις δικλοφενακ |